Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Pelizaeus-Merzbacher like disease (PMLD) is an autosomal recessive leukodystrophy sharing identical clinical and radiological features as X-linked Pelizaeus-Merzbacher disease (PMD).
No HPO annotations are available for this condition.
Pelizaeus-Merzbacher-like disease 1 (PMLD1) is a slowly progressive leukodystrophy that typically presents in the neonatal period or early infancy with nystagmus, often complicated by hypotonia and developmental delay. Over time the hypotonia may evolve into spasticity, and extrapyramidal movement abnormalities may emerge. Older children often manifest significant motor impairments that can also effect communication. Cognition is relatively preserved. The following detailed description of clinical manifestations is based on findings in individuals with a molecularly proven diagnosis [, , , , , , , , , , ]. Nystagmus (either rotatory or horizontal) appears in early infancy and is not present in all individuals.
Pelizaeus-Merzbacher-like disease 1 (PMLD1) should be suspected in individuals with the following classic clinical and neuroimaging findings:
Clinical findings
Nystagmus that typically presents during the neonatal period or early infancy
Mainly motor developmental delay and central hypotonia during infancy
No approved treatments are currently available for Pelizaeus-Merzbacher-like disease. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with Pelizaeus-Merzbacher-like disease 1 (PMLD1), the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis of Pelizaeus-Merzbacher-Like Disease 1
Table 6. Recommended Surveillance for Individuals with Pelizaeus-Merzbacher-Like Disease 1
Organ System |
|---|
No clinical trials have been registered for Pelizaeus-Merzbacher-like disease.
5 publications have been identified in PubMed for Pelizaeus-Merzbacher-like disease. Research spans Diagnostic / Biomarker (25%), Case Report / Case Series (25%), and Basic Science / Preclinical (25%).
Kagiava A (2026). [PMID: 41289961](https://pubmed.ncbi.nlm.nih.gov/41289961/). *EBioMedicine*. [Gene Therapy / Novel Therapeutics]
Saghir K (2025). [PMID: 39760459](https://pubmed.ncbi.nlm.nih.gov/39760459/). *Mov Disord Clin Pract*. [Case Report / Case Series]
Gong D (2025). [PMID: 40493033](https://pubmed.ncbi.nlm.nih.gov/40493033/). *J Gen Physiol*. [Basic Science / Preclinical]
Jabeen S (2025). [PMID: 41458849](https://pubmed.ncbi.nlm.nih.gov/41458849/). *Cureus*. [Diagnostic / Biomarker]
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 1:48 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Pelizaeus-Merzbacher-like disease
Source: GeneReviews — "Pelizaeus-Merzbacher-Like Disease 1"
Signs of upper motor neuron dysfunction (including spasticity, brisk deep tendon reflexes, and Babinski sign) usually affecting the lower limbs more than the upper limbs
Gait ataxia and other cerebellar signs
Mild choreiform movements and dystonia of the extremities that can become severe and disabling
Dysarthria and swallowing dysfunction
Neuroimaging findings. Findings on brain MRI include the following :
Source: GeneReviews — "Pelizaeus-Merzbacher-Like Disease 1"
(PMD) is an X-linked disorder caused by a hemizygous pathogenic variant in PLP1. The clinical presentation and radiologic appearance are similar to PMLD1. Most individuals present with neonatal nystagmus, hypotonia, global developmental delay, spasticity, gait ataxia, and choreoathetosis. Diffuse hypomyelination on brain MRI is observed in most individuals. Note that MRI evidence of brain stem involvement is more characteristic of PMLD1 than PMD. Both PMD and PMLD1 can present as an isolated spastic paraparesis; see . Hypomyelination with atrophy of the basal ganglia and cerebellum (see TUBB4A-Related Leukodystrophy) is caused by a heterozygous pathogenic variant in TUBB4A; affected individuals are typically simplex cases (i.e., a single occurrence in a family).
Source: GeneReviews — "Pelizaeus-Merzbacher-Like Disease 1"
Biomarker and diagnostic research for Pelizaeus-Merzbacher-like disease has been reported in the published literature.
Organ System | Evaluation | Comment |
|---|---|---|
Eyes | Ophthalmology | Assessment for optic atrophy nystagmus |
ENT | Audiology | Assessment for sensorineural hearing loss |
Gastrointestinal | Consultation w/gastroenterologist | Consideration of swallowing study to assess for swallowing dysfunction mgmt of constipation gastroesophageal reflux |
Musculoskeletal | Referral to an orthopedic surgeon for tone mgmt or orthopedic complications as indicated | Exam to assess for evidence of hip dislocation, joint contractures, scoliosis |
Neurologic | Consultation w/pediatric neurologist | Eval of movement disorders, tone, seizures Miscellaneous/ |
Other | Consultation w/nutritionist | Assessment of nutritional status needs Consultation w/developmental specialist |
Treatment of Manifestations in Individuals with Pelizaeus-Merzbacher-Like Disease 1 Manifestation | Treatment | Considerations/Other Developmental delay cognitive |
dysfunction | Accommodations in special classroom setting or w/aide | Recommendations from pediatric neurologist may be necessary to achieve maximum intellectual functional abilities. |
Spasticity | Oral GABA agonists (e.g., baclofen, diazepam) | For more focal spasticity, consider intramuscular injection of botulinum toxin. Physical therapy |
Dystonia | When associated w/spasticity, mgmt of dystonia w/baclofen or intramuscular botulinum toxin;trihexyphenidyl or tetrabenazine potentially helpful | In many cases, dystonia is refractory to medical mgmt. Scoliosis |
joint dislocation | Mgmt or surgical intervention by orthopedist | Swallowing |
dysfunction | Consider swallowing eval feeding therapy | Affected individuals are at risk of aspiration. Nutrition plan possible supportive feeding device to avoid malnutrition |
Dysarthria | Consider speech therapy to improve communication abilities | Augmentative communication approaches are often necessary. |
Seizures | Standard antiepileptic drug therapy | — |
Hearing loss | Standard approaches to hearing loss incl augmentative communication approaches; no evidence exists for cochlear implants in this context | See Hereditary Hearing Loss and Deafness Overview. |
Optic atrophy | Supportive approaches for the vision-impaired individual | Prevention of Secondary Complications Table 5. |
Prevention of Secondary Complications in Individuals with Pelizaeus-Merzbacher-Like Disease 1 Complication | Preventive Measure | Considerations/Other |
Constipation | Dietary management, laxatives, stool softeners | — |
Bone health | Regular monitoring of serum vitamin D calcium levels | If osteopenia is documented, consult w/bone health clinic to consider measures to avoid fracture. Community- acquired |
pneumonia | Good hand hygiene; influenza pneumococcal vaccines | Some affected individuals are reported to have deterioration of neurologic function w/febrile illness infection.1 Psychosocial consequences |
in caregiver | Involvement of social worker | 1. , Surveillance Table 6. |
Source: GeneReviews — "Pelizaeus-Merzbacher-Like Disease 1"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Pelizaeus-Merzbacher-Like Disease 1"
View trials for Pelizaeus-Merzbacher-like disease
Evaluation
Frequency/Comment |
|---|
Constitutional | Monitoring of general health growth; immunizations | Annually |
Eyes | Ophthalmology | Biannually unless symptoms develop |
Neurologic | Pediatric neurology assessment for disease progression, symptom control, review of medications | Annually Miscellaneous/ |
Other | Physiatrist physical/occupational therapy assessments for functional capacity equipment needs | Annually w/more frequent treatment visits once eval completed Assessment of communication abilities |
Source: GeneReviews — "Pelizaeus-Merzbacher-Like Disease 1"
Estimated prevalence: Unknown (Unknown prevalence).